Compare Costco Wholesale Corporation (COST) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs Novo Nordisk A/S — how do they compare? Costco Wholesale Corporation trades at $948.08 (market cap $418.79B), while Novo Nordisk A/S trades at $46.19 (market cap $207.85B). The key difference: Costco Wholesale Corporation is far larger — about 2× Novo Nordisk A/S's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| COST | NVO | |
|---|---|---|
Market Cap | $418.79B | $207.85B |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $63.98 |
52-Week Low | $849.63 | $35.29 |
Enterprise Value | $406.93B | $222.55B |
Dividend Yield | 0.62% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Costco Wholesale Corporation (COST) trades at $948.43, down 0.45% on the day, with technical indicators signaling a bearish trend amid neutral oscillators. The stock shows strong fundamentals with revenue growth to $275.24 billion in 2025 and consistent earnings beats, though it missed Q1 2026 estimates. Recent news highlights membership fee hikes and robust March sales, while analyst consensus remains bullish with a $1,120 price target.
The outlook for COST is positive due to steady revenue growth and high analyst confidence, but risks include elevated valuation multiples and competitive pressures. Investment opportunity lies in its scalable business model and membership-driven profits, though investors should monitor earnings consistency and macroeconomic impacts on consumer spending.
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
